41 results about "Genetic transfer" patented technology

This product is a work cell for cell therapy manufacturing, automating the entire manufacturing process, including cell concentration, separation, activation, gene transfer using viral vectors or electroporation, expansion culture, filling, finishing, and formulation. This product can provide a self-contained cleanroom environment with a robotic work cell, all within the size of a conference room or a small pickup truck.

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel elements that further improve expression. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.

The present invention relates to a method for cultivating transgenic plants having increased anthocyanin content and enhanced tolerance to biotic and abiotic stress environments. The method comprises transferring a bHLH35 gene into recipient plants using a genetic engineering transformation method, to obtain transgenic plants having increased anthocyanin content and tolerance to biotic and abiotic stress environments. The bHLH35 gene may be selected from a ChbHLH35 gene from Corydalis hemidicentra or an AtbHLH35 gene from Arabidopsis thaliana.

The application discloses a Buster transposon system and application thereof, and the system comprises AnBT, CrBT, HvBT, LcBT and LlBT transposons and corresponding transposases, the nucleotide sequences of the AnBT, CrBT, HvBT, LcBT and LlBT transposons are shown in SEQ ID No. 1-5, and the transposases are wild type or enhanced type. The application obtains key elements such as target site repeat (TSD) and terminal inverted repeat (TIR) of the AnBT, CrBT, HvBT, LcBT and LlBT transposons and corresponding transposase sequences through molecular reconstitution, and constructs a set of gene transfer vector systems. The AnBT, CrBT, HvBT, LcBT and LlBT vector systems can effectively mediate gene transfer through cell verification, and have great application potential in transgenic animal preparation and gene therapy.

Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.

The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and / or RSDs). Furthermore, applications of these transposase variants, the transpsoson, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.

To provide a method for producing a γδT cell population which expresses functional TCR or CAR by preparing large quantities of γδT cells with high purity and efficiently introducing a foreign gene encoding TCR or CAR into the obtained γδT cells.SOLUTION: The present invention provides a method for efficiently producing highly pure γδT cells introduced with foreign genes by culturing in the presence of IL-7 and IL-15 after stimulating the γδT cells with a bisphosphonic acid ester derivative, followed by gene introduction. When a T cell receptor (TCR) or a chimeric antigen receptor (CAR) is introduced as the foreign gene, the γδT cells in which TCR and CAR are functionally expressed can be obtained.SELECTED DRAWING: None

The application discloses a method for normalizing and comparing horizontal gene transfer (HGT) network, comprising the following steps: S1, using Bayesian probability model to normalize HGT according to sequencing amount; S2, in the HGT network, each genome is represented as a vertex, and if HGT occurs between two genomes, there is an edge between the two vertices; S3, using different classification levels to annotate genome sequence, and obtaining HGT network of different classification levels; S4, analyzing HGT network through several topological properties of graph density, transitivity, homophily and algebraic connectivity. The graph density, transitivity, homophily and algebraic connectivity are used to describe the network, and the HGT network is compared among samples in different groups, so that a new analysis direction is provided for the correlation between metagenome and human phenotype, and the metagenome can be more systematically modeled and analyzed by calculating various topological properties to analyze the HGT network.

To provide nucleic acid sequences, expression vectors (e.g., vector genomes) and plasmids, compositions and viral vectors in which the nucleic acid encodes Factor IX (e.g. human Factor IX).SOLUTION: A nucleic acid sequence encodes human Factor IX protein, where the nucleic acid has a reduced number of CpG di-nucleotides compared to a wild-type sequence encoding human Factor IX.SELECTED DRAWING: None

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.

This disclosure relates to adeno-associated virus variants capable of performing astrocyte-specific gene transfer. Administration of a recombinant viral vector containing nucleic acid encoding an AAV capsid protein mutant according to this disclosure enables the transfer and expression of therapeutic genes into specific astrocytes, thus demonstrating significant efficacy in the prevention or treatment of brain diseases.

The invention relates to a hybrid peptide consisting of amino acid sequences that bind nucleic acids on one side and cell membrane on the other side, in the fields of biology, genetics and chemistry. The invention particularly relates to a hybrid peptide developed to ensure the transfer of genes into the cell in the treatment of genetic diseases and incurable diseases such as some types of cancer.

Provided are cells that are resistant to mobile genetic elements or horizontal gene transfer, and methods for obtaining said cells. Also provided are methods for preventing the horizontal transfer of genetic information between a mobile genetic element and a first cell, cells making use of new genetic codons schemes and related subject matter, kits comprising mutually orthogonal cells, and mobile genetic elements. Also provided are methods of altering the susceptibility of a gene to mutations that alter the encoded amino acid sequence, methods for evolving or improving a protein, and methods for rendering a target gene more resistant to mutation. Additionally provided are uses of the cells for making polymers and methods comprising using the cells for making polymers.

The present application relates to the technical field of genetic engineering, and particularly relates to a salicylic acid glycosyltransferase and use thereof. The present application finds a new gene (nucleotide sequence as shown in SEQ ID NO. 3) in highland barley, the protein (amino acid sequence as shown in SEQ ID NO. 4) expressed by the gene can convert salicylic acid into salicylic acid glucoside, and improve the level of highland barley resistance to powdery mildew. The present application also performs in-vitro expression on the gene fragment, obtains the salicylic acid glycosyltransferase, and successfully prepares salicylic acid glucoside by taking glucose as a glycosyl donor and salicylic acid as a receptor in an in-vitro reaction. The present application also transfers the gene into tobacco, so that the salicylic acid glycosyltransferase is also expressed in the tobacco plant, further produces salicylic acid glucoside, and improves the value. The new gene, the recombinant vector, the recombinant bacteria, the protein and the transgenic plant provided by the present application all have good application prospects.

This invention discloses a method for remediating halogenated hydrocarbon pollution based on functional plasmid transformation, belonging to the field of environmental microbial remediation technology. The method first extracts plasmid DNA carrying functional genes from organobacteria with reductive dechlorination capabilities (organobacteria with halogen respiration). Then, the functional plasmid DNA and electron donors are directly added to halogenated hydrocarbon-contaminated samples containing indigenous microorganisms to construct a bio-enhanced remediation system. Finally, the system is cultured under anaerobic conditions to transform the functional plasmid into the indigenous microorganisms, thereby endowing or enhancing the indigenous microorganisms with the ability to reductively dechlorinate halogenated hydrocarbon pollutants. This invention avoids the ecological risks of directly introducing exogenous live bacteria. Through plasmid-mediated horizontal gene transfer, it rapidly activates and enhances the function of in-situ microbial communities, significantly improving the degradation rate and thoroughness of halogenated hydrocarbon pollutants, and providing an efficient, safe, and universally applicable technical means for in-situ bioremediation of contaminated sites.

To provide a technique for more surely achieving a higher viable cell rate while adopting a transposon method for CAR gene transfer in preparation of CAR-T cells.SOLUTION: Disclosed is a method for preparing a genetically modified T cell that expresses a chimeric antigen receptor, which comprises the following steps (i) to (iv): (i) a step of culturing the genetically modified T cell in a monocyte-depleted T cell-containing cell population; A step of preparing non-proliferative cells holding a viral peptide antigen, which are obtained by performing a culture treatment in the presence of a viral peptide antigen and a treatment for losing proliferation ability; (ii) a step of obtaining genetically modified T cells in which a target antigen-specific chimeric antigen receptor gene is introduced by a transposon method from a T cell-containing cell population subjected to a monocyte-reducing treatment; (iii) a step of mixing and co-culturing the non-proliferative cells prepared in step (i) and the genetically modified T cells obtained in step (ii); and (iv) a step of collecting cells after culture.SELECTED DRAWING: None

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for urinary incontinence and other urinary tract pathologies.

This application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs of synthetic antigen receptors (SARs), novel signaling chains for constructing SARs, novel antigen-binding domains, and novel methods for producing SAR-expressing cells. These novel methods and compositions are widely used in cell therapy.

Provided in the present invention are a hepatitis B virus receptor OATP and the use thereof. Specifically, provided in the present invention is the use of a substance in the preparation of an agent for preventing and / or treating hepatitis B virus (HBV) and / or hepatitis D virus (HDV) infections in an animal or diseases related to said infections, wherein the substance prevents or reduces the interaction between HBV and / or HDV and an organic anion transporting polypeptide (OATP) in the animal, and / or prevents or reduces the expression and / or function of OATP in the animal. Further provided in the present invention are a cell model and an animal model having susceptibility to HBV and / or HDV that are obtained by means of transferring an exogenous SLCO gene into a cell or expressing an exogenous OATP protein, and a method for establishing the models; a method for delivering a drug by means of targeting OATP, and a drug delivery vehicle targeting OATP; and an OATP-targeted delivery polypeptide vehicle derived from a hepadnaviridae surface antigen.

The invention relates to adeno-associated virus (AAV) serotype AAV-Rh74 and related AAV vectors, and AAV-Rh74 and related AAV vector mediated gene transfer methods and uses. In particular, AAV-Rh74 and related AAV vectors target polynucleotides to cells, tissues or organs for expression (transcription) of genes encoding therapeutic proteins and peptides, and polynucleotides that function as or are transcribed into inhibitory nucleic acid sequences.

Methods are provided for enhancing the genetic modification of target cells by automated centrifugal inoculation within a functionally closed cell processing platform. The process begins with the introduction of a cell suspension into a conical cell processing cartridge (CPC) that facilitates the settling and concentration of target cells. Genetic modification is achieved by injection of a gene transfer vector into the CPC, followed by controlled centrifugal inoculation, thereby enhancing vector-cell interactions by centrifugal force while maintaining optimal temperature and conditions. Optical sensors and automated feedback systems monitor and adjust centrifugation parameters to maximize transduction efficiency and cell viability. The methods include precise mixing, reagent delivery, washing to remove contaminants, and harvesting of genetically modified cells, all performed in a sterile environment. Additional features include buoyant microbubble separation, multi-modal centrifugation, and automated fluid handling via transfer syringe cartridges, ensuring efficient, contamination-free cell processing suitable for therapeutic applications.

The purpose of the present invention is to maintain and proliferate T cells, which are in a composition containing the T cells, into a cell group suitable for gene transfer. The present invention pertains to a method for culturing T cells characterized by comprising a step for bringing a composition containing T cells into contact with a composition containing a T cell surface antigen identification substance. The method is also characterized in that, in the composition containing T cells, the amount of the T cell surface antigen identification substance added is 0.0001-2.0 μg and / or 0.0001-20 pmol in terms of antigen recognizing moiety, per 106 T cells.

Using adults stem cells (ASC) including hematopoietic cell (HSC), endothelial progenitor cells and mesenchymal (MSC) stem cells; mobilizing ASC cells into the vascular system using a collection system of one of: (i) an apheresis. (ii) bone marrow; or (iii) direct collection of ASC from the peripheral blood; providing the ASC with a cryopreservation conservation container of about minus 80 degrees centigrade collecting the ASC for defrosting and placed in a sterile container; reprogramming stem cells (RSC) including at least one of (i) RSC by methylation patterns of DNA such as JMJD3 and HDAC; (ii) RSC by acetylation patterns of DNA such as HDAC; (iii) epigenetic programming with a protein of interest (ncRNA); using vectors of AAV or CMV to transfer to specific genes to provide proteins to enlarge physical conditions to lost during the aging process.

The invention is a cheap, portable, electricity-free electroporator for gene transfer in single cells. In order to transfer substances such as the gene DNA in cells, it generates electricity in during 20 microseconds in the range of about 200 volts to 5 kv. This causes a temporary opening of the cell pore in bacteria / cells and the targeted substance enters. The first part of the product: Cuvette holder: It is designed to hold the current electroporation cuvettes in a suitable size. The 2 copper connection cables from the piezoelectricity supply electricity to the cuvette. The second part of the product: Main case: It contains the 1st part of the product and also contains the piezoelectric system, cables, and button. It weighs approximately 30 grams and is a 3D printed single piece. Its dimensions are preferably 27 mm x 62 mm x 35 mm. The third part of the product: Button: Thanks to this button, electricity through piezo system is transferred to the cuvette with a single press.

The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and / or RSDs). Furthermore, applications of these transposase variants, the transposon, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.

To provide a method for producing reprogrammed cells from somatic cells without gene transfer.SOLUTION: (a) culturing somatic cells of a subject in a first medium free of LIF, a CCL2, and IL-6 and containing 2-mercaptoethanol to obtain precursors of pluripotent stem cells, and (b) culturing the precursors of pluripotent stem cells obtained in step (a) in a second medium containing any one or more selected from the group consisting of LIF, a CCL2, and IL-6 to produce pluripotent stem cells which are reprogrammed cells.SELECTED DRAWING: Figure 1

The invention provides application of cytokinin glycosyltransferase, and belongs to the technical field of genetic engineering. According to the invention, a novel gene (the nucleotide sequence is as shown in SEQ ID NO.3) in highland barley is found, and the protein expressed by the gene (the amino acid sequence is as shown in SEQ ID NO.4) can convert trans-zeatin into trans-zeatin 3-O-glucoside, so that the stress resistance level of the highland barley is improved. According to the invention, the gene segment is subjected to in-vitro expression to obtain cytokinin glycosyl transferase, and in an in-vitro reaction, glucose is successfully used as a glycosyl donor and trans-zeatin is successfully used as a receptor to prepare the trans-zeatin 3-O-glucoside. The gene is also transferred into tobacco, so that cytokinin glycosyltransferase is also expressed in a tobacco plant, transzeatin 3-O-glucoside is further generated, and the value of transzeatin 3-O-glucoside is improved. The novel gene, the recombinant vector, the recombinant bacteria, the protein and the transgenic plant provided by the invention have good application prospects.

The present invention addresses the problem of providing: a nerve cell analysis method with which the localized amount of TDP-43 in nerve cells can be analyzed without labeling TDP-43 with a fluorescent tag or the like and without carrying out gene transfer; a kit for carrying out the nerve cell analysis method; and a screening method for a prophylactic and / or therapeutic agent for a neurodegenerative disease. The present invention provides a nerve cell analysis method involving: a staining step for immunofluorescent staining of nerve cells using an anti-TDP-43 antibody and an antibody that recognizes a stress granule marker; a cell region identification step for identifying the cytoplasm and nuclei of the nerve cells; and an analysis step for analyzing a TDP-43-derived fluorescence signal and a stress granule marker-derived fluorescence signal in the cytoplasm, and analyzing the localized amount of TDP-43 in the nerve cells on the basis of the presence or absence of colocalization of a granular TDP-43 signal and a granular stress granule marker signal in the cytoplasm.

In some aspects, the disclosure provides recombinant AAV and nucleic acid constructs having novel inverted terminal repeat (ITR) proximal regions (IPRs). In some aspects, the disclosure relates to gene transfer methods using rAAVs described herein.

The invention discloses a simulation sequence generation method, system and equipment based on double genetic transfer matrixes. The method comprises the following steps: step 1, converting sequence data into state relation data; step 2, constructing a double transfer matrix; step 3, genetic algorithm optimization; 4, simulation data are generated based on the double matrixes; 5, outputting and applying data; according to the method, the object transfer matrix and the operation transfer matrix are constructed to realize separated modeling of the object and the operation, the genetic algorithm is combined to optimize the double matrixes generation by generation, and the object-operation legality mapping table is matched, so that the flexibility and controllability of the simulation data generation process are greatly enhanced; the generated simulation data effectively keeps the statistical characteristics and sequence structure details of the original data, the diversity of the generated data is improved, the consistency of object-operation combinational logic is guaranteed, the generated simulation data is ensured to be reasonable, large-scale real data does not need to be depended on, and the computing resource requirement is reduced.